They’re all at it these stent companies, trying to convince us that their offering has a bit more than the opposition. The new target is undoubtedly reduction in the need for DAPT therapy and Hong Kong based OrbusNeich has a very interesting proposition, combining drug elution with healing in the first dual therapy device.
Aside from that we’re discussing the merits of renal denervation in the light of new data presented at EuroPCR on Boston Scientific’s Vessix system. We’re still left wondering how and why renal denervation works, more more significantly why nobody’s really trying to find out as they bask in the knowledge that work it does.
Find the weekly review here.
published: May 31, 2013 in: Cardio, medlatest Editorial